Crescent Grove Advisors LLC Trims Holdings in Johnson & Johnson (NYSE:JNJ)

Crescent Grove Advisors LLC cut its stake in Johnson & Johnson (NYSE:JNJ) by 19.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,728 shares of the company’s stock after selling 919 shares during the period. Crescent Grove Advisors LLC’s holdings in Johnson & Johnson were worth $539,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Marshall Financial Group LLC raised its stake in shares of Johnson & Johnson by 110.9% in the 4th quarter. Marshall Financial Group LLC now owns 11,435 shares of the company’s stock valued at $1,654,000 after purchasing an additional 6,013 shares in the last quarter. Jamison Private Wealth Management Inc. boosted its holdings in shares of Johnson & Johnson by 93.7% in the 4th quarter. Jamison Private Wealth Management Inc. now owns 90,537 shares of the company’s stock valued at $13,093,000 after buying an additional 43,790 shares during the period. Asio Capital LLC grew its position in shares of Johnson & Johnson by 1.4% during the 4th quarter. Asio Capital LLC now owns 34,082 shares of the company’s stock valued at $4,929,000 after buying an additional 463 shares during the last quarter. Investment Research & Advisory Group Inc. lifted its holdings in Johnson & Johnson by 1.2% in the fourth quarter. Investment Research & Advisory Group Inc. now owns 15,155 shares of the company’s stock worth $2,192,000 after acquiring an additional 187 shares during the last quarter. Finally, Duncan Williams Asset Management LLC boosted its stake in Johnson & Johnson by 42.4% in the fourth quarter. Duncan Williams Asset Management LLC now owns 6,439 shares of the company’s stock valued at $931,000 after acquiring an additional 1,916 shares during the period. 69.55% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, Director Mark A. Weinberger purchased 1,000 shares of the firm’s stock in a transaction on Thursday, December 12th. The shares were bought at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the transaction, the director now directly owns 1,000 shares of the company’s stock, valued at approximately $147,220. This trade represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Company insiders own 0.16% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the company. Leerink Partners cut their price target on Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating on the stock in a report on Thursday, January 23rd. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $181.00 price objective on shares of Johnson & Johnson in a report on Thursday, January 23rd. Wolfe Research started coverage on Johnson & Johnson in a research note on Friday, November 15th. They set an “outperform” rating and a $190.00 target price on the stock. Bank of America lowered their target price on shares of Johnson & Johnson from $160.00 to $159.00 and set a “neutral” rating on the stock in a research note on Thursday, January 23rd. Finally, Guggenheim increased their price objective on shares of Johnson & Johnson from $156.00 to $162.00 and gave the company a “neutral” rating in a report on Wednesday, November 6th. Nine research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $170.44.

Johnson & Johnson Stock Performance

JNJ stock opened at $150.63 on Wednesday. The company has a market capitalization of $362.65 billion, a price-to-earnings ratio of 22.65, a P/E/G ratio of 2.45 and a beta of 0.51. The firm has a 50 day moving average of $147.81 and a two-hundred day moving average of $156.12. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $168.85.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, beating the consensus estimate of $1.99 by $0.05. The company had revenue of $22.52 billion for the quarter, compared to the consensus estimate of $22.44 billion. Johnson & Johnson had a return on equity of 34.35% and a net margin of 18.20%. The company’s revenue for the quarter was up 5.3% compared to the same quarter last year. During the same quarter last year, the company posted $2.29 earnings per share. As a group, equities analysts anticipate that Johnson & Johnson will post 10.56 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be paid a dividend of $1.24 per share. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 annualized dividend and a yield of 3.29%. Johnson & Johnson’s payout ratio is 74.59%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.